Ardelyx Inc. Common Stock (NASDAQ: ARDX)
Company Name:Ardelyx Inc. Common Stock
Stock Symbol:NASDAQ: ARDX
Class Period Start:08/06/2020
Class Period End (inclusive):07/19/2021
According to the filed complaint: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.